05 Mar, 16:14 - Indian

Nifty Bank 59055.85 (0.51)

Nifty Pharma 23005.5 (1.47)

SENSEX 80015.9 (1.14)

Nifty Midcap 100 57792.55 (1.52)

Nifty IT 30126.8 (-0.59)

Nifty Next 50 67722.2 (1.38)

Nifty Smallcap 100 16538.8 (1.58)

Nifty 50 24765.9 (1.17)

05 Mar, 16:14 - Global

NIKKEI 225 55278.06 (1.90)

HANG SENG 25321.35 (0.28)

S&P 6886 (-0.03)


Corporate News

You are Here : Home > News > Corporate News >

(07 Jan 2026, 12:01)

BSE SME Modern Diagnostic & Research Centre begins its market journey with a steady heartbeat

Modern Diagnostic & Research Centre traded at Rs 96 on the BSE, a premium of 6.67% compared with the issue price of Rs 90.


The scrip was listed at Rs 99.50, a premium of 10.56% compared with the initial public offer (IPO) price. The stock is currently down 3.52% over its listing price.

The counter hit a high of Rs 100 and a low of Rs 94.54. About 20.91 lakh shares of the company changed hands at the counter.

Modern Diagnostic and Research Centre's IPO was subscribed 350.49 times. The issue opened for bidding on 31 December 2025 and it closed on 2 January 2025. The price band of the IPO was set at Rs 85 to Rs 90 per share.

The IPO comprised fresh issue of 40,99,200 equity shares. The promoter and promoter shareholding diluted to 72.85% from 99.99% pre-IPO.

The company intends to utilize the net proceeds for funding capital expenditure for purchase of medical equipment towards establishment of new diagnostic centre & labs, funding working capital requirement, repayment of certain outstanding borrowings availed by company for general corporate purpose.

Ahead of the IPO, Modern Diagnostic and Research Centre on 30 December 2025, raised Rs 10.45 crore from anchor investors. The board allotted 11.61 lakh shares at Rs 90 per share to 9 anchor investor.

Modern Diagnostic & Research Centre (MDRC) is an established Indian diagnostics chain providing a comprehensive range of pathology and radiology services, with operations spanning 21 centres including 18 laboratories and 3 diagnostic centres across 8 states. The company offers advanced diagnostic solutions such as MRI, CT scans, ultrasound, digital X-rays, ECG, PFT and specialised cardiac and neurological services, supported by high-end infrastructure including a 3-Tesla MRI and a 128-slice CT scanner. Its pathology division covers routine to advanced testing, including molecular diagnostics, cytogenetics and oncology-focused panels, while added services like home sample collection, online reports and customised diagnostic packages enhance accessibility and convenience for patients and institutional clients. As of 30 September 2025, the company had 616 employees including consultants and doctors.

The company recorded revenue from operations of Rs 22.50 crore and net profit of Rs 2.99 crore for the period ended 30 June 2025.


More News

Capital Market Publishers India Pvt. Ltd

401, Swastik Chambers, Sion Trombay Road, Chembur, Mumbai - 400 071, India.

Formed in 1986, Capital Market Publishers India Pvt Ltd pioneered corporate databases and stock market magazine in India. Today Capitaline corporate database cover more than 35,000 listed and unlisted Indian companies. Latest technologies and standards are constantly being adopted to keep the database user-friendly, comprehensive and up-to-date.

Over the years the scope of the databases has enlarged to cover economy, sectors, mutual funds, commodities and news. Many innovative online and offline applications of these databases have been developed to meet various common as well as customized requirements.

While all the leading institutional investors use Capitaline databases, Capital Market magazine gives access to the databases to individual investors through Corporate Scoreboard. Besides stock market and company-related articles, the magazine’s independent and insightful coverage includes mutual funds, taxation, commodities and personal finance.

Copyright @ Capital Market Publishers India Pvt.Ltd

Designed, Developed and Content powered by CMOTS InfoTech (ISO 9001:2015 & ISO/IEC 27001:2022 Certified)

Site best viewed in Internet Explorer Edge ,   Google Chrome 115.0.5790.111 + ,   Mozilla Firefox 115.0.3 + ,   Opera 30.0+, Safari 16.4.1 +